SEC investigating Illumina over acquisition of cancer test developer Grail

  • 📰 CNBC
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 72%

Nigeria News News

Nigeria Nigeria Latest News,Nigeria Nigeria Headlines

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the. The agency also asked for statements and disclosures about the "conduct and compensation" of certain members of both Illumina and Grail's management, according to the filing.

Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in NG
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Nigeria Nigeria Latest News, Nigeria Nigeria Headlines